Role of the tachykinin NK(1) receptor in mediating contraction to 5-hydroxytryptamine and antigen in the mouse trachea.
Neuroimmune interactions are important in airway diseases such as asthma. We evaluated the role of the tachykinin NK(1) receptor in the contractile response of isolated trachea from tachykinin NK(1) receptor wild type (WT) and knockout (KO) mice, to the antigen ovalbumin and the contractile agonist serotonin (5-hydroxytryptamine). One percent ovalbumin induced contractions of tracheas obtained from ovalbumin-immunized and exposed mice. The tracheas from WT animals showed larger contractions compared to the KO mice. Tracheas from sensitized and ovalbumin-exposed animals released 5-hydroxytyptamine upon addition of ovalbumin. No higher levels of 5-hydroxytryptamine were released from tracheas of WT animals. Tracheas of non-sensitized animals did not release 5-hydroxytryptamine upon ovalbumin challenge. Responses to ovalbumin were abrogated by methysergide, a broad 5-hydroxytryptamine receptor antagonist. Exogenous 5-hydroxytryptamine contracted tracheas but WT tracheas responded significantly more. Atropine and tetrodotoxin (TTX) reduced 5-hydroxytryptamine-induced contractions of the WT tracheas, while they did not affect 5-hydroxytryptamine-induced contractions of KO tracheas. 5-Hydroxytryptamine-induced contractions from atropine- or TTX-treated WT tracheas did not differ significantly from the contractions of the KO tracheas. Single tachykinin NK(1) receptor antagonists SR140,333 and RP67,580 had no effect on 5-hydroxytryptamine-induced contractions. In conclusion, the 5-hydroxytryptamine-induced tracheal contraction includes a cholinergic mechanism that requires the presence of the tachykinin NK(1) receptor.
De Swert
Katelijne O
KO
Department Respiratory Diseases, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. Katelijne.Deswert@UGent.be
Lefebvre
Romain A
RA
Pauwels
Romain A
RA
Joos
Guy F
GF
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D008784:Methysergide / Q000494:pharmacology; D051379:Mice; D018345:Mice, Knockout; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology*; D009130:Muscle, Smooth / Q000502:physiology; D064729:Neurokinin-1 Receptor Antagonists; D010047:Ovalbumin / Q000494:pharmacology; D018040:Receptors, Neurokinin-1 / Q000502:physiology*; D012701:Serotonin / Q000378:metabolism* / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology; D013779:Tetrodotoxin / Q000494:pharmacology; D014132:Trachea / Q000502:physiology
D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; D012702:Serotonin Antagonists; D012701:Serotonin; D013779:Tetrodotoxin; D001285:Atropine; D010047:Ovalbumin; D008784:Methysergide